What is HC Wainwright’s Estimate for HRMY Q1 Earnings?

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Stock analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Harmony Biosciences in a report issued on Thursday, April 23rd. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings of $0.90 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $3.33 per share. HC Wainwright also issued estimates for Harmony Biosciences’ Q2 2027 earnings at $1.07 EPS.

A number of other analysts have also recently weighed in on HRMY. Zacks Research cut Harmony Biosciences from a “hold” rating to a “strong sell” rating in a research report on Thursday, March 26th. Truist Financial cut Harmony Biosciences from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. Weiss Ratings reissued a “hold (c)” rating on shares of Harmony Biosciences in a research report on Monday, December 29th. Needham & Company LLC cut their price objective on Harmony Biosciences from $46.00 to $44.00 and set a “buy” rating for the company in a research report on Wednesday, February 25th. Finally, UBS Group cut their price objective on Harmony Biosciences from $46.00 to $36.00 and set a “neutral” rating for the company in a research report on Wednesday, February 25th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $42.67.

Harmony Biosciences Price Performance

Shares of NASDAQ:HRMY opened at $30.80 on Friday. Harmony Biosciences has a fifty-two week low of $25.52 and a fifty-two week high of $40.87. The business has a 50-day moving average of $29.12 and a two-hundred day moving average of $32.70. The stock has a market capitalization of $1.78 billion, a P/E ratio of 11.37, a P/E/G ratio of 0.44 and a beta of 0.89. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.60 and a quick ratio of 3.58.

Harmony Biosciences (NASDAQ:HRMY) last announced its quarterly earnings results on Tuesday, February 24th. The company reported $0.38 earnings per share for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.46). Harmony Biosciences had a return on equity of 19.86% and a net margin of 18.29%.The company had revenue of $243.78 million during the quarter, compared to analyst estimates of $240.04 million. During the same period in the prior year, the firm earned $0.85 EPS. Harmony Biosciences’s quarterly revenue was up 21.1% on a year-over-year basis.

Insider Buying and Selling at Harmony Biosciences

In related news, CFO Sandip Kapadia sold 3,746 shares of the business’s stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $37.15, for a total transaction of $139,163.90. Following the completion of the transaction, the chief financial officer owned 24,521 shares of the company’s stock, valued at approximately $910,955.15. The trade was a 13.25% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 11.00% of the company’s stock.

Hedge Funds Weigh In On Harmony Biosciences

Large investors have recently made changes to their positions in the business. Inspire Investing LLC bought a new position in Harmony Biosciences during the first quarter valued at about $130,000. Foster & Motley Inc. increased its stake in Harmony Biosciences by 4.6% during the first quarter. Foster & Motley Inc. now owns 24,281 shares of the company’s stock valued at $680,000 after acquiring an additional 1,072 shares during the period. Louisiana State Employees Retirement System bought a new position in Harmony Biosciences during the first quarter valued at about $493,000. SG Americas Securities LLC increased its stake in Harmony Biosciences by 109.9% during the first quarter. SG Americas Securities LLC now owns 2,018,174 shares of the company’s stock valued at $56,529,000 after acquiring an additional 1,056,507 shares during the period. Finally, Evolve Private Wealth LLC bought a new position in Harmony Biosciences during the first quarter valued at about $522,000. Institutional investors and hedge funds own 86.23% of the company’s stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.